It is unlikely that HER2-targeted NIR-PIT alone will be successful in bladder cancer, but it could be used as part of a “cocktail” of APCs injected prior to NIR light administration in the bladder. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.